Inflammatory signatures distinguish metabolic health in African American women with obesity
Gerald V Denis, Paola Sebastiani, Kimberly A Bertrand, Katherine J Strissel, Anna H Tran, Jaromir Slama, Nilton D Medina, Guillaume Andrieu, Julie R Palmer, Gerald V Denis, Paola Sebastiani, Kimberly A Bertrand, Katherine J Strissel, Anna H Tran, Jaromir Slama, Nilton D Medina, Guillaume Andrieu, Julie R Palmer
Abstract
Obesity-driven Type 2 diabetes (T2D) is a systemic inflammatory condition associated with cardiovascular disease. However, plasma cytokines and tissue inflammation that discriminate T2D risk in African American women with obese phenotypes are not well understood. We analyzed 64 circulating cytokines and chemokines in plasma of 120 African American women enrolled in the Black Women's Health Study. We used regression analysis to identify cytokines and chemokines associated with obesity, co-morbid T2D and hypertension, and compared results to obese women without these co-morbidities, as well as to lean women without the co-morbidities. We then used hierarchical clustering to generate inflammation signatures by combining the effects of identified cytokines and chemokines and summarized the signatures using an inflammation score. The analyses revealed six distinct signatures of sixteen cytokines/chemokines (P = 0.05) that differed significantly by prevalence of T2D (P = 0.004), obesity (P = 0.0231) and overall inflammation score (P < E-12). Signatures were validated in two independent cohorts of African American women with obesity: thirty nine subjects with no metabolic complications or with T2D and hypertension; and thirteen breast reduction surgical patients. The signatures in the validation cohorts closely resembled the distributions in the discovery cohort. We find that blood-based cytokine profiles usefully associate inflammation with T2D risks in vulnerable subjects, and should be combined with metabolism and obesity counselling for personalized risk assessment.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241–1248. doi:
- Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17: 4–12.
- Johnson JA, Fried SK, Pi-Sunyer FX, Albu JB (2001) Impaired insulin action in subcutaneous adipocytes from women with visceral obesity. Am J Physiol Endocrinol Metab 280: E40–E49. doi:
- Stephens JM, Lee J, Pilch PF (1997). Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 272: 971–976.
- Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821–1830. doi:
- Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, et al. (2010) Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 299: E506–E515. doi:
- Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796–1808. doi:
- Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46: 2347–2355. doi:
- Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, et al. (2008) Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 28: 1654–1659. doi:
- Bigornia SJ, Farb MG, Mott MM, Hess DT, Carmine B, Fiscale A, et al. (2012) Relation of depot-specific adipose inflammation to insulin resistance in human obesity. Nutr Diabetes 2: e30 doi:
- Strissel KJ, Stancheva Z, Miyoshi H, Perfield JW 2nd, DeFuria J, Jick Z, et al. (2007) Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 56: 2910–2918. doi:
- Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, et al. (2003) Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 88: 5321–5326. doi:
- Browning LM, Krebs JD, Magee EC, Frühbeck G, Jebb SA. (2008) Circulating markers of inflammation and their link to indices of adiposity. Obes Facts 1: 259–265. doi:
- Kristiansen OP, Mandrup-Poulsen T. (2005) Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54 Suppl 2: S114–S124.
- Kahn SE, Zinman B, Haffner SM, O’Neill MC, Kravitz BG, Yu D, et al. (2006) Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in Type 2 diabetes. Diabetes 55: 2357–2364. doi:
- Bonora E, Willeit J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna R, et al. (1998) U-shaped and J-shaped relationships between serum insulin and coronary heart disease in the general population. The Bruneck Study. Diabetes Care 21: 221–230.
- Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. (2008) The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168: 1617–1624. doi:
- Phillips CM, Perry IJ (2013) Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab 98: E1610–E1619. doi:
- Kranendonk ME, van Herwaarden JA, Stupkova T, de Jager W, Vink A, Moll FL, et al. (2015) Inflammatory characteristics of distinct abdominal adipose tissue depots relate differently to metabolic risk factors for cardiovascular disease: distinct fat depots and vascular risk factors. Atherosclerosis 239: 419–427. doi:
- Sims EA (2001) Are there persons who are obese, but metabolically healthy? Metabolism 50: 1499–1504. doi:
- Després JP (2012) What is "metabolically healthy obesity"?: from epidemiology to pathophysiological insights. J Clin Endocrinol Metab 97: 2283–2285. doi:
- Marini MA, Succurro E, Frontoni S, Hribal ML, Andreozzi F, Lauro R, et al. (2007) Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. Diabetes Care 30: 2145–2147. doi:
- Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud’homme D, et al. (2005) The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 90: 4145–4150. doi:
- Aguilar-Salinas CA, Garcia EG, Robles L, Riaño D, Ruiz-Gomez DG, García-Ulloa AC, et al. (2008) High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 93: 4075–4079. doi:
- Cherqaoui R, Kassim TA, Kwagyan J, Freeman C, Nunlee-Bland G, Ketete M, et al. (2012) The metabolically healthy but obese phenotype in African Americans. J Clin Hypertens (Greenwich) 14: 92–96.
- Sebastiani P, Thyagarajan B, Sun F, Schupf N, Newman AB, Montano M, et al. (2017) Biomarker signatures of aging. Aging Cell 16: 329–338. doi:
- Rosenberg L, Adams-Campbell L, Palmer JR (1995) The Black Women’s Health Study: a follow-up study for causes and preventions of illness. J Am Med Womens Assoc 50: 56–58.
- Strissel KJ, Nicholas DA, Castagne-Charlotin M, Ko N, Denis GV (2016) Barriers to obtaining sera and tissue specimens of African American women for the advancement of cancer research. Clinical Medicine Insights: Women’s Health 2016. (Supplement to: Health Disparities in Women) 9 (Suppl 1): 57–61.
- Ogden CL, Carroll MD, Kit BK, Flegal KM (2014) Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA 311: 806–814. doi:
- Kones R, Rumana U (2014) Prevention of cardiovascular disease: updating the immensity of the challenge and the role of risk factors. Hosp Pract (1995) 42: 92–100.
- Menke A, Casagrande S, Geiss L, Cowie CC (2015) Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 314: 1021–1029. doi:
- Bastien M, Poirier P, Lemieux I, Després JP (2014) Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 56: 369–381. doi:
- Krishnan S, Rosenberg L, Djoussé L, Cupples LA, Palmer JR (2007) Overall and central obesity and risk of Type 2 diabetes in U.S. black women. Obesity (Silver Spring) 15: 1860–1866.
- Franssens BT, van der Graaf Y, Kappelle LJ, Westerink J, de Borst GJ, Cramer MJ, et al. (2015) Body weight, metabolic dysfunction, and risk of Type 2 diabetes in patients at high risk for cardiovascular events or with manifest cardiovascular disease: a cohort study. Diabetes Care 38: 1945–1951. doi:
- Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet 384: 755–765. doi:
- Moore LL, Chadid S, Singer MR, Kreger BE, Denis GV (2014) Metabolic health reduces risk of obesity-related cancer in Framingham Study adults. Cancer Epidemiol Biomarkers Prev 23: 2057–2065. doi:
- Park YM, White AJ, Nichols HB, O’Brien KM, Weinberg CR, Sandler DP (2017) The association between metabolic health, obesity phenotype and the risk of breast cancer. Int J Cancer 140: 2657–2666. doi:
- Akinyemiju T, Moore JX, Pisu M, Judd SE, Goodman M, Shikany JM, et al. (2018) A prospective study of obesity, metabolic health and cancer mortality. Obesity (Silver Spring) 26: 193–201.
- Frasca D, Ferracci F, Diaz A, Romero M, Lechner S, Blomberg BB (2016) Obesity decreases B cell responses in young and elderly individuals. Obesity (Silver Spring) 24: 615–625.
- Frasca D, Diaz A, Romero M, Blomberg BB (2017) Ageing and obesity similarly impair antibody responses. Clin Exp Immunol 187: 64–70. doi:
- Frasca D, Diaz A, Romero M, Vazquez T, Blomberg BB (2017) Obesity induces pro-inflammatory B cells and impairs B cell function in old mice. Mech Ageing Dev 162: 91–99. doi:
- Lamas O, Marti A, Martınez JA (2002) Obesity and immunocompetence. Eur J Clin Nutr 56 (Suppl 3): S42–S45.
- Palmer JR, Castro-Webb N, Bertrand K, Bethea TN, Denis GV (2017) Type II Diabetes and incidence of estrogen receptor negative breast cancer in African American women. Cancer Res 77: 6462–6469. doi:
- Andrieu G, Tran AH, Strissel KJ, Denis GV (2016) BRD4 regulates breast cancer dissemination through Jagged1/Notch1 signaling. Cancer Res 76: 6555–6567. doi:
- Perreault M, Zulyniak MA, Badoud F, Stephenson S, Badawi A, Buchholz A, et al. (2014) A distinct fatty acid profile underlies the reduced inflammatory state of metabolically healthy obese individuals. PLoS One 9: e88539 doi:
- Vasudevan AR, Wu H, Xydakis AM, Jones PH, Smith EO, Sweeney JF, et al. (2006) Eotaxin and obesity. J Clin Endocrinol Metab 91: 256–261. doi:
- Metcalf TU, Cubas RA, Ghneim K, Cartwright MJ, Grevenynghe JV, Richner JM, et al. (2015) Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Aging Cell 14: 421–432. doi:
- Iyengar NM, Brown KA, Zhou XK, Gucalp A, Subbaramaiah K, Giri DD, et al. (2017) Metabolic obesity, adipose inflammation and elevated breast aromatase in women with normal Body Mass Index. Cancer Prev Res 10: 235–243.
- Denis GV, Palmer JR (2017) "Obesity-associated" breast cancer in lean women: Metabolism and inflammation as critical modifiers of risk. Cancer Prev Res (Phila) 10: 267–269.
- Denis GV, Sebastiani P, Andrieu G, Tran AH, Strissel KJ, Lombardi FL, et al. (2017) Relationships among obesity, Type 2 diabetes, and plasma cytokines in African American Women. Obesity (Silver Spring) August 25 doi:
- Sebastiani P, Perls TT (2016) Detection of significant groups in hierarchical clustering by resampling. Front Genet 7: 144 doi:
Source: PubMed